LLC-WRC 256
1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
LLC-WRC 256 is a breast carcinosarcoma cell line derived from Walker rats, known for its ability to facilitate the growth of herpes simplex, pseudorabies, and vaccinia viruses. These cells exhibit high tumorigenicity in suckling rats and share similarities with the basal-B molecular subtype of human breast cancer cell lines. Notably, cholesterol has been found to impede the proliferation and glutamine metabolism of LLC-WRC 256 tumor cells. Additionally, Krest has shown inhibitory effects on the growth of LLC-WRC 256. Furthermore, the circRNA circSlc7a11 has been identified as a regulator of rat bone cancer pain development by modulating LLC-WRC 256 cell proliferation and apoptosis through diverse signaling mechanisms.
Why choose LLC-WRC 256 from AcceGen?
LLC-WRC 256 from AcceGen is a compelling choice due to its high viability and quality. The cell line is prepared under optimal and standardized conditions, ensuring sterility and reliability. Furthermore, advanced cryopreservation techniques are employed, maintaining the integrity and viability of the cells. AcceGen’s rigorous quality control measures guarantee the authenticity and consistency of the LLC-WRC 256 cell line, making it a trusted resource for researchers and ensuring reliable and reproducible results in various applications.
| Product Code | LLC-WRC256; Walker/LLC-WRC 256; Walker-256; Walker-Ca.256; Walker 256; W256 |
| Species | Rattus Norvegicus |
| Cat.No | ABC-TC0596 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Disease | AdenoCarcinoma |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Rat Breast Cancer Cell Lines |
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The LLC-WRC 256 cell line offers diverse applications in cancer research. Firstly, it enables the investigation of drug effects on cell proliferation of tumor cells, providing valuable insights into potential therapeutic interventions. This cell line plays a crucial role in studying the modulation of oxidative stress and the release of soluble biomarkers, which are key factors in tumor proliferation and angiogenesis. By examining these aspects in LLC-WRC 256, researchers can identify molecules with significant functions in cancer development. Moreover, LLC-WRC 256 facilitates screening for effective combinations of compounds with cytotoxic or cytostatic potential, aiding in the inhibition of tumor growth. The chosen combinations can then be utilized in subsequent assays, such as apoptosis evaluation and expression analysis, further contributing to our understanding of cancer biology and potential treatment strategies.
